LIFECORE BIOMEDICAL, INC. Contract with Customer, Liability, Noncurrent
LIFECORE BIOMEDICAL, INC. (LFCR) had Contract with Customer, Liability, Noncurrent of $0 as of 2025-12-31, per its 10-KT filed 2026-03-16.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2026-03-16
- 2025-12-31: Contract with Customer, Liability, Noncurrent $0.00.
- 2025-09-30: Contract with Customer, Liability, Noncurrent $1.17M.
- 2025-06-30: Contract with Customer, Liability, Noncurrent $2.56M.
- 2025-05-25: Contract with Customer, Liability, Noncurrent $3.02M.
| Period end | Contract with Customer, Liability, Noncurrent | Contract with Customer, Liability, Noncurrent as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-KT · filed 2026-03-16 | |
| 2025-09-30 | $1.17M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $2.56M 10-Q · filed 2025-11-06 | |
| 2025-05-25 | $3.02M 10-KT · filed 2026-03-16 | |
| 2025-02-23 | $4.42M 10-Q · filed 2025-04-03 | |
| 2024-11-24 | $4.88M 10-Q · filed 2025-01-02 | |
| 2024-08-25 | $4.79M 10-Q · filed 2024-10-04 | |
| 2024-05-26 | $4.96M 10-KT · filed 2026-03-16 | $4.70M 10-K · filed 2024-08-26 |
| 2023-11-26 | $321.00K 10-Q · filed 2024-08-09 | |
| 2023-08-27 | $1.69M 10-Q · filed 2024-08-09 | |
| 2023-05-28 | $2.94M 10-K · filed 2024-08-26 | $2.90M 10-K · filed 2024-03-20 |
| 2022-05-29 | $0.00 10-K · filed 2024-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |